Aims Cannabidiol (CBD) is a cannabis‐derived medicinal product with potential application
in a wide‐variety of contexts; however, its effective dose in different disease states remains …

The interest in cannabis-based products for the treatment of refractory epilepsy has
skyrocketed in recent years. Marijuana and other cannabis products with high content in Δ …

Background Cannabidiol has been used for treatment-resistant seizures in patients with
severe early-onset epilepsy. We investigated the efficacy and safety of cannabidiol added to …

Cannabidiol (CBD) is one of the cannabinoids with non-psychotropic action, extracted from
Cannabis sativa. CBD is a terpenophenol and it has received a great scientific interest …

Epilepsy and cannabidiol: a guide to treatment | Cairn.info Cairn.info, Matières à réflexion
Cairn.info, Matières à réflexion Aucune suggestion trouvée Compte personnel Adresse email …

Summary Objective Since 2014, cannabidiol (CBD) has been administered to patients with
treatment‐resistant epilepsies (TREs) in an ongoing expanded‐access program (EAP). We …

This meta-analysis paper describes the analysis of observational clinical studies on the
treatment of refractory epilepsy with cannabidiol (CBD)-based products. Beyond attempting …

Review evidence for cannabinoids as adjunctive treatments for treatment-resistant epilepsy.
Systematic search of Medline, Embase and PsycINFO was conducted in October 2017 …

Cannabidiol (CBD) is a major active component of the Cannabis plant, which, unlike
tetrahydrocannabinol (THC), is devoid of euphoria-inducing properties. During the last 10 …

Background Cannabidiol (CBD), which is one major constituent of the Cannabis sativa plant,
has anti-seizure properties and does not produce euphoric or intrusive side effects. A plant …